What is HC Wainwright’s Estimate for KPRX FY2024 Earnings?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) – Equities research analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Kiora Pharmaceuticals in a report issued on Monday, November 11th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $1.28 per share for the year, down from their previous estimate of $1.58. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Kiora Pharmaceuticals’ current full-year earnings is $1.17 per share. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q4 2024 earnings at ($0.74) EPS, Q1 2025 earnings at $0.67 EPS and FY2025 earnings at ($2.76) EPS.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09.

Kiora Pharmaceuticals Stock Performance

Shares of NASDAQ KPRX opened at $3.44 on Thursday. The firm’s 50-day simple moving average is $3.53 and its 200 day simple moving average is $4.28. Kiora Pharmaceuticals has a fifty-two week low of $3.00 and a fifty-two week high of $8.98.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals makes up approximately 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.